Physician profile
Joyce Nuqui Barlin
NPI 1962553479
$207,614.68
in general payments reported to CMS, 2019-2025
17 companies · $44K in 2025
The $44K reported for 2025 was more than what 97% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $12K · 2021: $13K · 2022: $30K · 2023: $27K · 2024: $51K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Consulting Fee: $23K · Travel and Lodging: $8,381 · Food and Beverage: $2,546 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,695.00 |
| Consulting Fee | $22,776.94 |
| Travel and Lodging | $8,381.28 |
| Food and Beverage | $2,546.02 |
| Education | $110.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $159,190.87 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $31,271.85 | 2021-2025 | Keytruda |
| Daiichi Sankyo INC. | $3,500.00 | 2025 | |
| Genmab U.S., INC. | $3,446.25 | 2022-2024 | Epkinly |
| Corcept Therapeutics | $3,316.94 | 2025 | |
| Glaxosmithkline, LLC. | $2,247.24 | 2024 | Jemperli, Zejula |
| Eisai INC. | $2,055.00 | 2024 | |
| Clovis Oncology, INC. | $1,799.00 | 2019-2020 | |
| Abbvie INC. | $417.61 | 2024-2025 | |
| Seagen INC. | $197.70 | 2022-2023 | |
| Ethicon US, LLC | $109.06 | 2019-2022 | |
| Tesaro, INC. | $63.16 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Barlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.